Le Lézard
Classified in: Health, Covid-19 virus
Subjects: TRI, FDA

Kintor Pharma Announces PD-L1/TGF-? dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China


SUZHOU, China, Oct. 21 , 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of PD-L1/TGF-? dual-targeting antibody (GT90008) for the treatment of advanced solid tumours was approved by the National Medical Products Administration (NMPA) of China on 21 October 2021.

GT90008 is a PD-L1/TGF-? dualtargeting antibody which has a high activity in inhibiting both PD-L1 and TGF-?R2. GT90008 has the potential to be a best-in-class drug globally. Kintor Pharma obtained an exclusive license in Greater China for GT90008 from US-based company Gensun in August 2020.

Dr. Youzhi Tong, founder, Chairman and CEO of Kintor Pharma, commented, "We are delighted to obtain the approval from NMPA to conduct the clinical trial of PD-L1/TGF-? dual-targeting antibody. GT90008 is the second novel antibody drug that has entered the clinical stage. The rapid progress from in-license to IND approval has demonstrated our team's great execution capability. Though there has been headwind on dual-targets antibody of this category, we are confident with our antibody and actively exploring the combination therapies with our GT90001(ALK-1) antibody on advanced tumours. We wish the combo design of GT90008 and GT90001 would benefit patients with advanced tumours. "

About Kintor Pharmaceutical Limited

Kintor Pharmaceutical Limited is developing and commercializing a robust pipeline of innovative small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs, including COVID-19, prostate, breast and liver cancer, alopecia and acne. For more information, visit www.kintor.com.cn.

 

SOURCE Kintor Pharmaceuticals


These press releases may also interest you

at 01:05
Olympus Corporation ("Olympus" ? Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi), has clarified the direction of its medical business with the aim of achieving further growth and profitability by elevating the standard...

at 01:00
Covis Pharma Group (the "Company"), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic...

at 01:00
- Roche introduces three artificial intelligence (AI)-based, deep learning image analysis Research Use Only (RUO) algorithms developed for breast cancer, which is the second most common cancer in the world with an estimated 2.3 million new cases in...

at 00:04
Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, held an award ceremony with the British...

at 00:01
U.S. News & World Report today published the inaugural edition of the Best Hospitals for Maternity, which expands the U.S. News Best Hospitals rankings, ratings and data offerings. This expansion builds upon more than 32 years of guiding patients and...

6 déc 2021
Today Stride Health, the leader in portable benefits for independent workers, announced its support of the "Gig Workers' Week of Action" initiative by the Centers for Medicare & Medicaid Services (CMS) to help raise awareness among independent...



News published on 21 october 2021 at 10:33 and distributed by: